As Factor I mediates the effects of other endogenous complement inhibitors implicated in AMD, notably Factor H, establishing the ophthalmic manifestations of CFI type 1 variants can yield important diagnostic and therapeutic biomarkers for complement gene defects in general (5). Here, CFH is linked to age-related macular degeneration.